Literature DB >> 448071

Human transfer factors: structural properties suggested by HPRP chromatography and enzymatic sensitivities.

D R Burger, A A Vandenbark, W Dunnick, W Kraybill, G D Daves, R M Vetto.   

Abstract

Leukocyte extracts containing human transfer factor (TF) were fractionated by exclusion chromatography, and the active fraction (Sephadex G25, Fraction IIIa) was subjected to high pressure, reverse phase (HPRP) chromatography and enzymatic degradation. TF activity was assessed by the systemic transfer of dermal skin test reactivity from KLH-immunized donors to naive recipients. Preparative HPRP chromatography resolved Fraction IIIa into multiple chromophoric regions, two of which demonstrated transfer of KLH reactivity. Alkaline phosphatase treatment of Fraction IIIa converted the major ultraviolet-absorbing component, 5'-inosine monophosphate, to inosine and resulted in TF activity being restricted to one region. This HPRP region (R1A) contained less than 1% of the UV254 active material in Fraction IIIa but greater than 90% of the reactivity. The sensitivity of TF to pronase, proteinase K, phosphodiesterase I, and phosphodiesterase II was evaluated by inhibition of systemic transfer of KLH reactivity. Pronase and proteinase K destroyed systemic transfer activity and the pronase destruction could be inhibited with traysylol. Phosphodiesterase I, a 3' exonuclease, destroyed activity, whereas phosphodiesterase II, a 5' exonuclease, did not. The data are consistent with a phosphodiester-containing polypeptide in the structure of human TF for KLH reactivity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 448071

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Effects of human transfer factor on the migration of guinea-pig macrophages: is there an antigen-specific activity?

Authors:  I L Sargent; M R Salaman
Journal:  Immunology       Date:  1980-09       Impact factor: 7.397

2.  Transfer factor in restoration of cell mediated immunity in lung cancer patients.

Authors:  T Fujisawa; Y Yamaguchi; H Kimura
Journal:  Jpn J Surg       Date:  1983-07

3.  In vivo modification of delayed type hypersensitivity by small molecular weight components derived from human leucocytes: partial purification of components causing amplification of response.

Authors:  A A Gottlieb; S B Sutcliffe
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

4.  Randomized controlled trial of transfer factor immunochemotherapy as an adjunct to surgical treatment for primary adenocarcinoma of the lung.

Authors:  T Fujisawa; Y Yamaguchi; H Kimura; M Arita; M Shiba; M Baba
Journal:  Jpn J Surg       Date:  1984-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.